🧬 Turning Back Inflammaging: Thymulin's Immunotherapy Breakthrough

🧬 Can a thymus-derived peptide help overcome age-related resistance to cancer immunotherapy? A fascinating new study identifies thymulin as a key regulator of age-associated inflammation. In preclinical models, thymulin reduced pro-inflammatory myeloid activity, inhibited NF-κB signaling, enhanced T-cell immunity, and restored responsiveness to anti-PD-L1 therapy in aged hosts. While clinical translation remains to be established, the work highlights the intriguing thymus–myeloid axis as a potential therapeutic target in older adults with cancer. 🎙️ More insights on Dr RR Baliga's Podkast for the Kurious Doc—Where Curiosity Meets Clarity!